Details of the subjects with congenital hypothyroidism and documentation of the initial diagnosis and treatment have been published previously.4 5 Subjects were then followed up annually to the age of 5 years. Paediatricians were sent a questionnaire asking for dated measurements of height, weight, and head circumference closest to each birthday, details of changes in the dose of thyroxine during the previous year, and the results of all thyroid function tests.
children with congenital hypothyroidism, identified by neonatal screening, were examined in relation to paired measurements of plasma thyroxine (n= 1945), free thyroxine (n=836), triiodothyronine (n=480), and free triiodothyronine (n=231), and estimated daily dose of thyroxine at the time of blood sampling. Overall, plasma TSH was above 7 mUll in 1280 out of 2960 samples (43%); the percentage was not related to severity of hypothyroidism at diagnosis. Mean values for thyroxine and free thyroxine, and to a lesser extent free triiodothyronine, were consistently lower in samples with TSH concentrations over 7 mU/l and this was the case in patients with either severe or less severe hypothyroidism. Raised TSH concentrations were also associated with lower mean doses of thyroxine (,ug/Ikgday) but here the mean doses of thyroxine in children with severe hypothyroidism were higher than in the children with less severe hypothyroidism. The mean dose of thyroxine associated with low/normal TSH values was highest in the first 6 months and fell progressively. Thyroxine dose was significantly related to thyroxine and free thyroxine concentrations but not to triiodothyronine and free triiodothyronine and the latter appeared to 4 years are the subjects of this study. These children were split into two approximately equal sized groups according to the pretreatment plasma thyroxine concentration as described previously5; 195 had pretreatment thyroxine concentrations of 30 nmolIl or less, and 223 had concentrations over 30 nmol/l. In the first group, treatment was started at a median age of 18 days (5th-95th centiles 10-38 days) and in the second at 20 days (5th-95th centiles 12-173 days); three of the latter cases did not start treatment until after the age of 1 year.
TSH AND THYROID HORMONE RESULTS
Altogether 3752 measurements of plasma TSH obtained after starting treatment and up to the age of 4 years were recorded by the register. Six hundred and forty three of these values were obtained within 28 days after a change in thyroxine dose (including temporary withdrawal of treatment) and were excluded to avoid difficulties of interpretation due to recent changes of treatment6; 61% of these latter results were obtained before the age of 6 months and in 71% plasma TSH was above 7 mU/l. Of the remaining 3109 values, it was possible to calculate body weight (and hence thyroxine dose/kg/day) at the time 2960 samples were taken for TSH assay (see below); these latter results form the basis of this report. The median number of TSH results for each patient in the group with severe hypothyroidism was seven (5th-95th centiles 1-13) compared with six (5th-95th centiles 2-14) in the group with less severe hypothyroidism.
Many TSH results were reported as either above (n= 109) or below (n=485) the limits of assay sensitivity, or in the normal range (n=24). These results were assigned values of 40 mU/l, 1 mU/l, and 2 mU/l respectively. The remaining values showed a positively skewed distribution. In the initial analysis TSH results were divided into two groups, 7 mU/l or less ('normal'), and above 7 mU/l ('raised'); in subsequent analyses the TSH results were divided into four groups, corresponding roughly to 'low/normal' (1 mU/l or less), 'normal' (2-7 mU/l), 'mildly raised' (8-20 mU/l), and 'markedly raised' (over 20 mU/l) TSH concentrations.
THYROID HORMONE CONCENTRATIONS
Thyroid hormone status had been assessed predominantly using thyroxine measurements but free thyroxine, triiodothyronine, and free triiodothyronine had also been used; all hypothyroidism.
[n=76]
In keeping with a number of previous [4] [5] [6] [7] [8] [9] In most accounts of thyroxine requirements in hypothyroid adults and children, suppression of plasma TSH into the normal range has been used as the marker of adequate treatment, rather than plasma thyroid hormone concentrations. While the present study showed a close relationship between TSH and plasma thyroxine and free thyroxine, and to a lesser extent free triiodothyronine, the significant overlap of thyroid hormone concentrations between samples with raised and low/normal TSH values illustrates the limitation of using measurements of thyroid hormone concentration to monitor treatment. However, the use of TSH alone to monitor treatment has the drawback that plasma TSH may take several weeks to readjust to a change in thyroxine dosage.6 In contrast, plasma thyroxine and free thyroxine rapidly reach new equilibria'2 and this can be helpful in monitoring the initial stages of treatment in congenital hypothyroidism when TSH concentrations may remain abnormal for some time. Estimation of thyroxine or free thyroxine may also help identify when a persistent increase of TSH is due to poor compliance with treatment, leading to either unexpectedly low thyroid hormone concentrations, or apparently adequate concentrations after improved compliance immediately before a clinic visit.
It is becoming widely accepted that recently introduced highly sensitive assays for TSH provide the most reliable method of monitoring treatment in hypothyroidism, particularly as they can also detect overtreatment leading to subnormal TSH concentrations.13 14 
